A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Summary

A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer. The main questions it aims to answer are: * What are the most tolerable doses of ONCT-534? (Phase 1) * Does ONCT-534 have anti-tumor activity at tolerable doses? (Phase 2) This is a dose escalation and expansion study where participants will receive daily oral doses of ONCT-534.

Timeline

Start

2023-09-20

Primary completion

2024-09-12

Completion

2024-09-12

Outcome

Outcome not reported

Stopped: “Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.”

Drugs

Indications